{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ06264",
      "entity_text" : "sarilumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Although the development of persistent ADAs and NAbs was associated with lower circulating sarilumab levels, no correlation was observed between ADA development and either AEs or loss of efficacy in patients who had previously achieved ACR50 or EULAR good response (improvement of DAS28-CRP> 1.2 units and an overall DAS28-CRP < = 3.2).",
  "reading_complete" : "2020-07-28T15:31:08Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:25:59Z",
  "trigger" : "levels",
  "evidence" : [ "sarilumab levels" ],
  "pmc_id" : "6702535",
  "score" : 0
}